€ million |
|
Note |
|
2021 |
|
2020 |
---|---|---|---|---|---|---|
Profit after tax |
|
|
|
3,065 |
|
1,994 |
Depreciation/amortization/impairment losses/reversals of impairment losses |
|
|
|
1,762 |
|
1,938 |
Changes in inventories |
|
|
|
-472 |
|
-85 |
Changes in trade accounts receivable |
|
|
|
-310 |
|
-84 |
Changes in trade accounts payable/refund liabilities |
|
|
|
433 |
|
7 |
Changes in provisions |
|
|
|
196 |
|
-110 |
Changes in other assets and liabilities |
|
|
|
-121 |
|
-123 |
Neutralization of gains/losses on disposal of fixed assets and other disposals |
|
|
|
-24 |
|
-98 |
Other non-cash income and expenses |
|
|
|
86 |
|
39 |
Operating Cash Flow |
|
|
4,616 |
|
3,477 |
|
thereof: from discontinued operations |
|
|
|
– |
|
– |
|
|
|
|
|
|
|
Payments for investments in intangible assets |
|
|
|
-355 |
|
-150 |
Payments from the disposal of intangible assets |
|
|
|
39 |
|
88 |
Payments for investments in property, plant and equipment |
|
|
|
-1,066 |
|
-1,413 |
Payments from the disposal of property, plant and equipment |
|
|
|
7 |
|
35 |
Payments for investments in financial assets |
|
|
|
-269 |
|
-278 |
Payments for acquisitions less acquired cash and cash equivalents (net) |
|
|
|
-4 |
|
-11 |
Proceeds from the disposal of other financial assets |
|
|
|
69 |
|
340 |
Payments for the acquisition of non-financial assets |
|
|
|
– |
|
-500 |
Proceeds from the disposal of non-financial assets |
|
|
|
– |
|
501 |
Payments from other divestments |
|
|
|
1 |
|
– |
Payments for the disposal of assets held for sale |
|
|
|
– |
|
-8 |
Proceeds from the disposal of assets held for sale less transferred cash and cash equivalents |
|
|
|
– |
|
55 |
Investing Cash Flow |
|
|
-1,578 |
|
-1,340 |
|
thereof: from discontinued operations |
|
|
|
– |
|
-8 |
|
|
|
|
|
|
|
Dividend payments to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
-181 |
|
-168 |
Dividend payments to non-controlling interests |
|
|
|
-8 |
|
-7 |
Profit withdrawal by E. Merck KG, Darmstadt, Germany |
|
|
|
-567 |
|
-512 |
Proceeds from new borrowings of financial debt from E. Merck KG, Darmstadt, Germany |
|
|
|
471 |
|
390 |
Repayment of financial debt to E. Merck KG, Darmstadt, Germany |
|
|
|
-393 |
|
-382 |
Repayment of bonds |
|
|
|
-317 |
|
-2,724 |
Proceeds from the issuance of bonds |
|
|
|
– |
|
2,486 |
Payments from new borrowings of other current and non-current financial debt |
|
|
|
388 |
|
3,561 |
Repayment of other current and non-current financial debt |
|
|
|
-1,896 |
|
-4,166 |
Financing Cash Flow |
|
|
-2,504 |
|
-1,522 |
|
thereof: from discontinued operations |
|
|
|
– |
|
– |
|
|
|
|
|
|
|
Changes in cash and cash equivalents |
|
|
|
534 |
|
615 |
Changes in cash and cash equivalents due to currency translation |
|
|
|
9 |
|
-40 |
Cash and cash equivalents as of January 1 |
|
|
|
1,355 |
|
781 |
Cash and cash equivalents as of December 31 |
|
|
1,899 |
|
1,355 |